Shots:
- The P-III FIDELIO-DKD study in CKD and T2D enrolled over 13,000 patients with early kidney damage and more advanced stages of kidney disease. The data were presented at the ASN Kidney Week 2020 and published in the NEJM based on which Bayer submitted finerenone for marketing authorization in the US and the EU
- Results: Finerenone reduced the key secondary composite CV endpoint consistently in patients with CKD and T2D, with or without history of cardiovascular disease. Additionally, it reduced the non-fatal MI, non-fatal stroke, or hospitalization for heart failure by 14%
- Finerenone (BAY 94-8862) is an investigational novel, non-steroidal, selective MRA that has been shown to block many of the harmful effects of MR overactivation which mainly causes kidney and CV damage through inflammatory and fibrotic processes
Click here to read full press release/ article | Ref: Bayer | Image: Bayer
The post Bayer’s Finerenone Demonstrates Positive Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes first appeared on PharmaShots.
